Full Press Release Details
Cybin to Participate in the H.C. Wainwright 2nd
Annual Psychedelics Conference on December 6, 2021
TORONTO, CANADA November 29, 2021 Cybin Inc.
(NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to
TherapeuticsTM is pleased to announce that Doug Drysdale, Cybin s Chief Executive Officer, will participate in a fireside chat at the
2nd Annual H.C. Wainwright Psychedelics Conference being held virtually on Monday, December 6, 2021.
Mr. Drysdale s fireside chat will be available on demand beginning on December 6, 2021 at 7:00 a.m. ET. To listen to the event, please click
here to access the webcast. The archived webcast will also be available on the Company s investor relations website on the Events & Presentations page.
Cybin is a leading ethical biopharmaceutical
company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and
founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug
discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Investor & Media Contacts:
Vice President, Investor Relations